SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...

Myriad Medical Supply today announced that the company has upgraded its portfolio of disposable medical products and hired David Nichols, a veteran leader in the healthcare industry, to serve ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing ...

Gastric cancer diagnostics companies are Abbott, BD, Bio-Rad Laboratories, Roche, Siemens Healthineers, Thermo Fisher Scientific, Pillar Biosciences, ETC ...

The rising rate of colon cancer in young people can't be caused by diet alone, doctors say. Microplastics, sleep, and ...

This article will explore what DLBCL is and how clinical trials can potentially lead to breakthroughs in treatment.

In the following sections, this press release dives into the science behind Mitolyn, shares real-world success stories, and ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with ...

$290,000 of MYRIAD GENETICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "S.708 - legislation to require a ...

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...